Mounjaro: What You Should Know About the New Type 2 Diabetes Medicine
Come May 13th, 2022 a new medicine for Type 2 Diabetes known as Mounjaro (Tirzepatide) became available in the market. It is a first-of-its-class…
The purpose of this study is to find out whether an inhaled, ultra-rapid-acting insulin works as well as mealtime insulin shots. Possible benefits of inhaled insulin include that it works very fast. That means kids can take it with their first bite of food and there is less of a chance of having low blood sugar between meals. Additionally, they could need fewer daily insulin shots.
If you qualify, you may receive study-related care and study medication or an approved medication at no charge. You may also receive compensation for travel expenses.
To take part in the study, participants should be:
CEO and Medical Director
Sub-Investigator
Sub-Investigator
CRC Manager
Clinical Research Coordinator
Clinical Research Coordinator
Clinical Research Coordinator
Clinical Research Coordinator
Clinical Research Coordinator
Have questions? Call us at (515) 329-6800 or email us at info@iowadiabetes.com.